Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Various factors move the S&P 500, including earnings, macro data, rate expectations, and sector rotations. This intro covers the main influences on index direction.
17,835 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
A $250,000 SPIA promises $1,600 a month for life, but it comes with lock-in, fees, and a trade-off between predictabl...
An ABA survey reveals strong public backing for guardrails on stablecoin yields linked to bank risk, underscoring reg...
Jim Cramer says he cringes at owning AT&T or Verizon as Bernstein flags Starlink competition risk, signaling a potent...
Pershing Square seeks an NYSE debut for both its closed-end fund and parent, targeting a $5-$10 billion raise and a B...
Rising electricity costs driven by AI data centers are reshaping the landscape for utility stocks. This deep dive exp...
Finance America’s 2025 profit jumps 175% as originations hit $2.4 billion, reflecting robust demand for home equity l...
An academic paper analyzes UWM's 2021 broker ultimatum tied price and finds rivals shaved an average of 5 basis point...
Shiba Inu token eyes a decisive price move as on-chain data hints at a potential breakout, even as Shibarium shows si...
Could Penguin Solutions be the next stock to deliver outsized gains? This article breaks down the growth engines, pot...
Thinking about buying Cava Group stock? This guide breaks down three crucial lessons to help you evaluate momentum, f...
A laid-off professional returns to work for $18,000 less annually and faces the looming question: how will this affec...